Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
fentanyl
|
| gptkbp:approvedBy |
gptkb:FDA
2006 |
| gptkbp:ATCCode |
N02AB03
|
| gptkbp:brand |
fentanyl buccal tablet
|
| gptkbp:contains |
gptkb:fentanyl_citrate
|
| gptkbp:contraindication |
opioid non-tolerant patients
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:form |
gptkb:tablet
100 mcg 200 mcg 400 mcg 600 mcg 800 mcg |
| https://www.w3.org/2000/01/rdf-schema#label |
Fentora
|
| gptkbp:indication |
breakthrough cancer pain
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Cephalon
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:relatedTo |
gptkb:Actiq
|
| gptkbp:riskFactor |
addiction
overdose respiratory depression |
| gptkbp:routeOfAdministration |
buccal
|
| gptkbp:bfsParent |
gptkb:Cephalon
|
| gptkbp:bfsLayer |
7
|